Cadrenal Therapeutics, Inc.
CVKD
$1.19
-$0.01-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.82M | 8.84M | 9.35M | 9.70M | 9.33M |
| Depreciation & Amortization | 2.10K | 2.00K | 6.90K | 6.70K | 6.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.65M | 12.05M | 13.46M | 14.67M | 14.40M |
| Operating Income | -11.65M | -12.05M | -13.46M | -14.67M | -14.40M |
| Income Before Tax | -11.54M | -11.89M | -13.24M | -14.39M | -14.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.54 | -11.89 | -13.24 | -14.39 | -14.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.54M | -11.89M | -13.24M | -14.39M | -14.11M |
| EBIT | -11.65M | -12.05M | -13.46M | -14.67M | -14.40M |
| EBITDA | -11.65M | -12.05M | -13.45M | -14.67M | -14.39M |
| EPS Basic | -4.92 | -5.65 | -6.70 | -8.83 | -9.70 |
| Normalized Basic EPS | -3.08 | -3.53 | -4.19 | -5.52 | -6.06 |
| EPS Diluted | -4.92 | -5.65 | -6.70 | -8.83 | -9.70 |
| Normalized Diluted EPS | -3.08 | -3.53 | -4.19 | -5.52 | -6.06 |
| Average Basic Shares Outstanding | 9.49M | 8.54M | 7.97M | 7.02M | 6.08M |
| Average Diluted Shares Outstanding | 9.49M | 8.54M | 7.97M | 7.02M | 6.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |